CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line.

Abstract

<p>Isogenic oncogenic progression in HBEC 3KT. Immortalized HBECs with (A) lenti-<i>KRas</i><sup>V12</sup>, (B) lenti-<i>KRas</i><sup>V12</sup> and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i><sup>V12</sup>, sh<i>p53</i>, and <i>myc</i> overexpression. Only lenti-<i>KRas</i><sup>V12</sup> cells are still moderately protected by CDDO-Me, but further oncogenic changes eliminate the radioprotective effects of CDDO-Me. (D) HBEC 30KT are protected by CDDO-Me. (E) HCC 4017, a NSCLC isolated from the same patient from which HBEC 30KT was derived, are unprotected by CDDO-Me. (F) Increasing concentrations to 50 nM still enhances clonogenic survival of HBEC 30KT, but actually seems to decrease survival in HCC 4017 after 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).</p

Similar works

Full text

thumbnail-image

FigShare

redirect
Last time updated on 12/02/2018

This paper was published in FigShare.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.